Walleye Capital’s Nurix Therapeutics NRIX Stock Holding History

Walleye Capital’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-74,869	Closed	-$1.42M	–	4781
2025 Q4	$1.42M	Buy	+74,869	New	+$1.08M	﹤0.01%	2155
2025 Q3	–	Sell	-62,298	Closed	-$710K	–	4920
2025 Q2	$710K	Sell	62,298 -11,762	-16%	-$127K	﹤0.01%	2335
2025 Q1	$880K	Buy	+74,060	New	+$1.24M	﹤0.01%	2077
2024 Q3	–	Sell	-24,882	Closed	-$519K	–	5701
2024 Q2	$519K	Buy	+24,882	New	+$387K	﹤0.01%	3482
2021 Q4	–	Sell	-10,546	Closed	-$316	–	2249
2021 Q3	$316	Buy	+10,546	New	+$325K	0.01%	990

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Walleye Capital's NRIX Position: Q1 2026 in Review

Walleye Capital sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 74,869 shares — an estimated $1.42M sold.

Walleye Capital first reported a position in NRIX in Q3 2021 and held it in 5 quarters. The position peaked at $1.42M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Walleye Capital reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 74,869 Nurix Therapeutics shares in Q1 2026, an estimated $1.42M.
Walleye Capital first reported a position in Nurix Therapeutics in Q3 2021 and held it in 5 quarters.
Walleye Capital's Nurix Therapeutics position peaked at $1.42M in Q4 2025.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.